Diane Medved Harper, MD, MPH, MS
Professor and Chair
Department of Family and Geriatric Medicine &
Departments of Obstetrics Gynecology
School of Medicine
8911 Coltsfoot Trace
Prospect, KY 40059, USA
• (1994-1995) MPH, University of Kansas Medical School (Biostats /Epidemiology)
• (1982-1986) MD, University of Kansas Medical School (KUMC)
• (1980-1982) SM, Massachusetts Institute of Technology (Polymerics)
• (1976-1980) SB, Massachusetts Institute of Technology (Chemical Engineering)
POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS
•(2005) High Resolution Anoscopy, Biopsy and Treatment, University of California, San Francisco
• (2000) US PHS Primary Care Fellowship, Washington DC
• (2001) Faculty Development: McMaster University, Teaching Evidence Based Medicine, Hamilton, ON
• (1995) Robert Wood Johnson Generalist Physician Faculty Fellowship
• (1994) Faculty Fellow: Stanford Faculty Development Program, Medical Decision Making, Palo Alto, CA
•(1990) Fellow: Colposcopy Training: Harvard Medical School, Louis Burke, MD
•(1986) Colposcopy Training: Kansas University Medical Center, John Calkins, MD
• (1987-1990) Resident: Kansas University Medical Center, Department of Family Medicine
• (1986-1987) Intern: Kansas University Medical Center, Department of Gyn and Obstetrics
• (1985) Fellow: National Institutes of Health, Inter-Institute Genetics Clinic
•(1983) Fellow: Clendening History of Medicine Fellowship, KUMC
Her research interests include: HPV associated diseases, HPV vaccines, High resolution anoscopy, Colposcopy/Vaginoscopy/Vulvoscopy, HPV associated diseases guideline development, Cervical cancer prevention, Early detection and treatment, Quality of life measures incorporated into screening guidelines, Shared decision making around screening decisions, Shared decision making around cervical cancer prevention, HPV biomarkers for clinical screening/triage/prediction, Primary screening strategies for cervical cancer, Primary care responsibility to screening, Precursors, Early Detection, Technology Assessment, Cost effectiveness analysis, Quality of life, Immunologic response, HPV etiology, Practice pattern variations for screening and treatment, Patient education, Telecolposcopy/medicine, Optical characteristics of dysplastic precursors, Identification of in vivo lesions by laser light, PET scanning of brain function during screening and diagnostic cervical cancer Procedures. Osteoporosis/HRT: Drug choice, Prevention strategies.
AWARDS AND HONORS
• (1976) First Place Award. Chemistry Division, The International Science and Engineering Fair, for Medved DL
• (1977)London Youth International Science Fortnight, for Medved DL
• (1978) United States National Womens Crew Team
• (1979) Betsy Schumaker Award for the most outstanding woman athlete at Massachusetts
• (1980) United States Olympic Finalist for Womens Crew Team, [Olympics boycotted]
• (1990) Most Outstanding Third-Year Family Medicine Resident Award presented for performance in Internal Medicine at Bethany Medical Center-KUMC
• (1991) Jack L. Mulligan, MD Teacher of the Year Award
• (1994) Saks Fifth Avenue Leadership Recognition Award
• (1994) ACLS Honor Roll
• (1994) Colposcopy Recognition Award, American Society of Colposcopy and Cervical Pathology
• (1995) UKC Trustees Faculty Fellowship
• (1995) NAPCRG Award for Research Grant Development in Family Medicine
• (1988) KUMC Housestaff Research Award: Second Place
• (1988) KAFP Outstanding Research Award. Kansas Academy of Family Physicians 38th Annual Scientific Assembly, Wichita KS
• (1988) AAFP Second Place. Scientific Exhibits, 1988, American Academy of Family Physicians 40th Annual Scientific Assembly
• (1990) KAFP First Place. Ciba-Geigy Resident Award, Kansas Academy of Family Physicians 40th Annual Scientific
• (1990) AAFP First Place. Scientific Exhibits, American Academy of Family Physicians 42nd Annual Scientific Assembly
• (1992) American Cancer Society Cancer Control Career Development Award
• (1996) Robert Wood Johnson Generalist Physician Faculty Scholar Award
• (1998) Top Ten National Educators in Family Medicine. 50th Anniversary Scientific Convocation of the AAFP • (1998) Teacher of the Year Award, Dartmouth Family Practice Residencies
• (2000) United States Public Health Service Primary Care Policy Fellowship, under the Secretary of HHS (Shalala)
• (2000) ASCCP Best Research of the Year Award from the American Society of Colposcopy and Cervical Pathology
• (2001) Alpha Omega Alpha, Dartmouth Medical School
• (2002 ASCCP Best Research of the Year Award from the “Harper DM, Noll WW, Raymond M, Belloni D, Cole B.
• (2002) Role Model of the Year Award Family Medicine Residency Dartmouth Lebanon Campus, Dartmouth Medical School
• (2002-2003) AAFP Active Teacher Recognition Award
• (2003) Dartmouth Undergraduate Journal of Science Special Recognition Feature for Teaching
• (2004) Consumers Research Council of America, Top Family Doctor in US, 2004-2005
• (2005) STFM Best Research Paper of 2003-2004, Honorable Mention, Society of Teachers of Family Medicine
• (2005) Dartmouth Undergraduate Journal of Science Special Feature for Clinical Teaching
• (2006) Distinguished Service Award, EuroGin, Paris (International recognition of work towards the prevention of cervical cancer)
• (2005) New Hampshire Family Physician of the Year, 2006
• (2007) Prevention Magazine Top Ten Health Heroes of the Year. March 2008 publication
• (2008) Woman of Excellence of MIT Womens Crew Awarded at the 35th anniversary of womens crew at MIT, October 4, 2008, Cambridge, MA
• (2008) Science Pioneers Award for Scientific Achievement, 18, 2008
• (2009) Jack L. Mulligan, MD Teacher of the Year Award
• (2010) Jack L. Mulligan, MD Teacher of the Year Award
• (2011) Outstanding Athletic Award for MIT Woman Alumna
• (2011) van Gogh Cinematic Vision Award, Amsterdam Film Festival: The Greater Good a film about HPV vaccination in the US
• (2011) 2nd annual Koroni Award, KoronisFest, a Festival for health communications in all media
• (2011) Jack L. Mulligan, MD Teacher of the Year Award
• (2012) Jack L. Mulligan, MD Teacher of the Year Award
• (2012) MIT Educational Councilor
• (2013) Kansas City Super Doctors Designation
• (2013) STFM Excellence in Education Award
• (2013) Prix Monte-Carlo Femme de lAnnée
• (2013) Jack L. Mulligan, MD Teacher of the Year Award
• (2014) Kansas City Super Doctors Designation
• (2015) Curtis G Hames Research Award
• (2015) Executive Leadership in Academic Medicine, ELAM Scholar
• (2015) Notre Dame de Sion Alumna of the Year
1. McElroy P, Medved DL, Roylance D. Weathering of Sheet Molding Compounds. Environmental Degradation of Engineering Materials in Aggressive Environments. Proceedings of the Second International Conference on Environmental Degradation of Engineering Materials. 1981; 473-479.
2. Harper DM, Walstatter BS, Lofton BJ. Anesthetic Blocks for Loop Electrosurgical Excision Procedure. J Fam Pract. 1994; 39(3):249-256.
3. Harper DM. Pain and Cramping Associated with Cryosurgery. J Fam Pract. 1994; 39(6): 551-557.
4. Harper, DM, Johnson CA, Harper WH, Liese BS. Prenatal Predictors of Cesarean Section due to Labor Arrest. Arch Gynecol Obstet. 1995; 256(2): 67-74. doi: 10.1007/BF00634711
5. Harper DM. The Determination of Diagnostic Probabilities for Human Papillomavirus Testing in the Evaluation of an Abnormal Screening Papanicolaou Smear. University of Kansas Press, Department of Preventive Medicine. 1995; 1-200.
6. Harper DM. The Paracervical Block Diminishes Cramping Associated with Cryosurgery. J Fam Pract. 1997; 44: 71-75.
7. Perry G, Brown E, Thornton R, et al. The Effect of Digoxin on Mortality and Morbidity in Patients with Heart Failure. New England Journal of Medicine. 1997; 336(8): 525-533. doi: 10.1056/NEJM199702203360801
8. Comninellis NB, Harper DM. Does Comprehensive Preventive Medicine Training Enhance Clinical Prevention? Fam Med. 1997; 29(2): 112-114.
9. Ferris DG, Harper DM. The Efficacy of Topical Benzocaine Gel in Providing Anesthesia Prior to Cervical Biopsy and Endocervical Curettage. Journal of Lower Genital Tract Disease. 1997; 1(4): 221-227.
10. Ferris DG, Cox JT, Burke L, et al. Colposcopy Quality Control: Establishing Colposcopy Criterion Stands for the NCI ALTS Trial. Journal of Lower Genital Tract Disease. 1998; 2(4): 195-203.
11. Pogue BW, Burke GC, Weaver J, Harper DM. Multi-wavelength digital colposcopy to aid early detection of cervical cancer. Biomedical Optical Spectroscopy and Diagnostics. Therapeutic Laser Applications, Trends in Optics and Photonics series. 1998; 22: 118-121.
12. Stern JE, Givan AL, Gonzalez JL. Harper DM, White HD, Wira CR. Leukocytes in the cervix: A Quantitative Evaluation of Cervicitis. Obstet Gynecol. 1998; 91: 987-992.
13. Harper DM, Cobb JL. Cervical Mucosal Block Effectively Reduces the Pain and Cramping from Cryosurgery. J Fam Pract. 1998; 47: 285-289.
14. Tobia DM, Shamos EF, Harper DM, Walch SE, Currie JL. The Benefits of Group Music at the 1996 Music Weekend for Women with Cancer. J Cancer Educ. 1999; 14: 115-119.
15. Harper DM, Cobb JL. Is it Cost Effective to Use a Mucosal or Paracervical Block to Relieve the Pain and Cramping from Cryosurgery? A Decision Model. J Fam Pract. 1999; 48: 285-290.
16. Harper DM, Hildesheim A, Cobb JL, Greenberg M, Vaught J, Lorincz A. Collection Devices for Human Papillomavirus. J Fam Pract. 1999; 48: 531-535.
17. Pogue BW, Mycek MA, Harper DM. Image Analysis for Discrimination of Cervical Neoplasia. J Biomed. Optics. 2000; 5(1): 72-82.
18. Taylor LA, Sorensen SV, Ray NF, Halpern MT, Harper DM. Cost effectiveness of the conventional Papanicolaou test with a new adjunct to cytological screening for squamous cell carcinoma of the uterine cervix and its precursors. Arch Fam Med. 2000; 9: 713-721.
19. Harper, DM, Moncur MM, Harper WH, Burke GC, Rasmussen CA, Mumford MC. The technical performance and clinical feasibility of telecolposcopy. J Fam Pract. 2000; 49: 623-627.
20. Harper DM, Parke KA, Cobb JL Moncur MM. Self-reported desire to improve colposcopic impressions. Archives of Gynecology and Obstetrics. 2000; 264: 137-142.
21. Harper DM, Mayeaux EJ, Daaleman TP, Woodward LD, Ferris DG, Johnson CA. The Natural History of Cervical Cryosurgical Healing: Debridement of the Cervical Eschar has Minimal Effect. J Fam Pract. 2000; 49: 694-700.
22. Harper DM, Mayeaux EJ, Daaleman TP, Johnson CA. Healing Experiences after Cervical Cryosurgery. J Fam Pract. 2000; 49: 701-706.
23. Pogue BW, Kaufman HB, Zelenchuk A, et al. Analysis of acetic acid-induced whitening of high-grade squamous intraepithelial lesions. J Biomed Optics. 2001; 6: 397-403.
24. Harper DM, Noll WW, Belloni DR, Cole BF. Randomized Clinical Trial of PCR Determined HPV Detection Methods: Self-Sampling vs. Clinician-Directed – Biological Concordance and Womens Preferences. Am J Obstet Gynec. 2002; 186: 365-373.
25. Harper DM, Noll WW, Raymond R, Duncan LT, Belloni DR, Cole BF. Tampon samplings with longer cervico-vaginal cell exposures are equivalent to two consecutive swabs for the detection of high-risk HPV. Sexually Transmitted Diseases. 2002; 29: 628-636.
26. Harper DM, Raymond M, Noll WW, Belloni DR, Cole BF. Factors affecting the detection rate of human papillomavirus. Ann Fam Med. 2003; 1: 221-227.
27. Becker HI, Longacre MR, Harper DM. Beyond the Pap: Assessing Womens Priorities for Annual Exams. J Womens Health. 2004; 13: 791-798.
28. Harper DM, Schmid-Saugeon P, Zelenchuk A, Pitts JD, Kaufman HB. Kinetic Patterns of Colposcopic acetowhitening associated with cervical pathology. Obstet Gynecol. 2004; 103: 18S.
29. Harper DM, Schmid-Saugeon P, Zelenchuk A, Pitts JD, Kaufman HB. Quantitative Measurements of acetowhitening may provide an adjunct to colposcopy to identify cervical intraepithelial neoplasia 2 and 3. Obstet Gynecol. 2004; 103: 19S.
30. Harper DM, Huh WW, Alvarez RD, Guido RS, McIntyre-Seltman K, Schomacker KT. The Effect of the Menstrual Cycle phases on the optical algorithms developed from diffuse reflectance. Obstet Gynecol. 2004; 103: 22S.
31. Garcia F, Huh WW, Cestero RM, Gold MA, McIntyre-Seltman K, Harper DM. Effect of age, acetic acid application method, and target distance on optical detection of CIN 2/3. Obstet Gynecol. 2004; 103: 81S.
32. Huh WK, Cestero RM, Garcia FA, et al. Optical detection of high-grade cervical intraepithelial neoplasia in vivo: results of a 604-patient study. Am J Obstet Gynecol. 2004; 190(5): 1249-1257.
33. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004; 364: 1757-65.
34. Villa LL, Costa RL, Petta CA, et al. Prophylactic Quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncology. 2005; 6(5): 271-278.
35. Wiley DJ, Harper DM, Elashoff D, et al. How condom use, number of receptive anal intercourse partners and history of external genital warts predict risk for external anal warts. International Journal of STD & AIDS. 2005; 16(3): 203-211.
36. Monsonego J, Harper DM. HPV infections and cervical cancer prevention. Priorities and new directions. Gynecologic Oncology. 2005; 96(3): 830-839. doi: 10.1016/j.ygyno.2004.11.021
37. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial. Obstetrical & Gynecological Survey. 2005; 60(7): 484-484.
38. Harper DM, Franco EL, Wheeler CM, et al. Sustained Efficacy up to 4.5 years of a bivalent L1 virus like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised controlled trial. Lancet. 2006; 367: 1247-1255. doi: 10.1016/S0140-6736(06)68439-0
39. Villa LL, Ault KA, Giuliano AR, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine. 2006; 24(27-28): 5571-5583. doi: 10.1016/j.vaccine.2006.04.068
40. Garland S, Hernandez-Avila M, Wheeler CM, et al. Efficacy of a quadrivalent HPV (Types 6/11/16/18) L1 VLP Vaccine against external anogenital, vaginal, and cervical disease. A randomized controlled trial. N Engl J Medicine. 2007; 356(19): 1928-1943.
41. Garland SM, Steben M, Hernandez-Avila M, et al. An evaluation of non-inferiority in antibody response to human papillomavirus (HPV) 16 in subjects vaccinated with monovalent (HPV 16) and quadrivalent (HPV 6, 11, 16, 18) L1 virus like particle vaccines. Clinical and Vaccine Immunology. 2007; 14(6): 792-795.
42. Joura EA, Leodolter S, Hernandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6/11/16/18) L1 virus like particle vaccine against high-grade vulval and vaginal lesions: A combined analysis of three clinical trials. Lancet. 2007; 369(9574): 1693-1702.
43. Saslow D, Castle PE, Cox JT, et al. Gynecologic Cancer Advisory Group. Garcia F. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA: a Cancer Journal for Clinicians. 2007; 57(1): 7-28.
44. Cobb KL, Bachrach LK, Sowers M, et al. Randomized trial of the effect of oral contraceptives on bone mass and stress fractures in female runners. Medicine & Science in Sports & Exercise. 2007; 39(9): 1464-1473.
45. Cutts FT, Franceschi S, Goldie S, et al. Human Papillomavirus and HPV vaccines: a review. Bulletin of the World Health Organization. 2007; 85(9): 719-726.
46. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007; 369: 2161-2170. doi: 10.1016/S0140-6736(07)60946-5
47. Wiley DJ, Elashoff D, Masongsong EV, et al. Smoking enhances risk for new external genital warts in men. International Journal of Environmental Research & Public Health. 2009; 6(3): 1215-1234. doi: 10.3390/ijerph6031215
48. Romanowski B, de Borba PC, Naud PS, et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet. 2009; 374(9706): 1975-1985. doi: 10.1016/S0140-6736(09)61567-1
49. FUTURE I/II Study Group (Harper DM), Dillner J, Kjaer SK, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ. 2010; 341: c3493. doi: 10.1136/bmj.c3493
50. Insinga RP, Perez G, Wheeler CM, et al. Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women. Cancer Epidemiol Biomarkers Prev. 2010; 19(6): 1585-1594.
51. Stoler MH, Vichnin MD, Ferenczy A, et al. The accuracy of colposcopic biopsy: Analyses from the placebo arm of the Gardasil clinical trials. Int J Cancer. 2011; 128(6): 1354-1362. doi: 10.1002/ijc.25470.
52. Harper DM. IOM (Institute of Medicine). Adverse Effects of Vaccines: Evidence and Causality. Washington, DC: The National Academies Press. 2011.
53. Szarewski A, Poppe WA, Skinner SR, et al. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18. Int J Cancer. 2012; 131(1): 106-116. doi: 10.1002/ijc.26362
54. Wheeler CM, Castellsagué X, Garland SM, et al. Cross-protective efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: end-of-study (4-year) analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012; 13(1): 100-110. doi: 10.1016/S1470-2045(11)70287-X
55. Heitmann ER, Lankachandra KM, Wall J, et al. 3q26 Amplification Is an Effective Negative Triage Test for LSIL: A Historical Prospective Study. PLoS One. 2012; 7(7): e39101. doi: 10.1371/journal.pone.0039101
56. Roset Bahmanyar E, Paavonen J, Naud P, et al. Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial. Gynecol Oncol. 2012; 127(3): 440-450. doi: 10.1016/j.ygyno.2012.08.033
57. Swarezski A, Skinner SR, Garland SM, et al. Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low risk HPV Types (PATRICIA randomised trial): an unexpected observation. Journal of Infectious Diseases. 2013; 208: 1391-1396.
58. Verdenius I, Harper DM, Harris GD, et al. Predictors of Three Dose On-Time Compliance with HPV4 Vaccination in a Disadvantaged, Underserved, Safety Net Population in the US Midwest. PLoS ONE. 2013; 8(8): e71295. doi: 10.1371/journal.pone.0071295
59. Geraets DT, van Doorn LJ, Kleter B, Colau B, Harper DM, Quint WG. Long-Term Follow-Up of HPV16-Positive Women: Persistence of the Same Genetic Variant and Low Prevalence of Variant Co-Infections. PLoS ONE. 2013; 8(11): e80382. doi: 10.1371/journal.pone.0080382
60. Harper DM, Verdenius I, Ratnaraj F, Arey AM, Rosemergey B, Malnar GJ, Wall J. Quantifying Clinical HPV4 Dose Inefficiencies in a Safety Net Population. PLoS ONE. 2013; 8(11): e77961.
61. Harper DM, Verdenius I, Harris GD, et al. The influence of free quadrivalent human papillomavirus vaccine (HPV4) on the timely completion of the three dose series. Preventive Medicine. 2014; 61: 20-25. doi: 10.1016/j.ypmed.2014.01.007
62. Harper DM, Irons BB, Alexander NM, et al. Quantifying the Decisional Satisfaction to Accept or Reject the Human Papillomavirus (HPV) Vaccine: A Preference for Cervical Cancer Prevention. PLoS ONE. 2014; 9(2): e88493. doi: 10.1371/journal.pone.0088493
63. Harper DM, Groner JA. Positive High-Risk HPV Test with Negative Cytology-A Conundrum and Blessing of Our Latest Technology. Cancer Epidemiol Biomarkers Prev. 2014; 23(1): 10-11. doi: 10.1158/1055-9965.EPI-13-0708
64. Groner JA, Harris GD, Harper DM. Reduction in HPV prevalence–no evidence to support HPV vaccination reduces HPV prevalence. Journal of Infectious Diseases. 2014; 209(8): 1302-1304. doi: 10.1093/infdis/jit836
65. Harper DM. Conclusions about HPV4 efficacy based on alternate dosing schedules and less than three dose immunogenicity is inappropriate. Journal of Infectious Diseases. 2014.
66. Sandri KJ, Verdenius I, Bartley MJ, et al. Urban and rural safety net health care system clinics: no disparity in HPV4 vaccine completion rates. PLoS One. 2014; 9(5): e96277. doi: 10.1371/journal.pone.0096277
67. Else BM, Bartley MJ, Arey AM, et al. In a Safety Net Population HPV4 Vaccine Adherence Worsens as BMI Increases. PLoS ONE. 2014; 9(7): e103172.
68. Harper DM, Alexander NM, Ahern DA, et al. Women have a preference for their male partner to be HPV vaccinated. PLoS One. 2014; 9(5): e97119.
69. Alexander NM, Harper DM, Comes JC, et al. Intent to continue cervical cancer screening after HPV vaccination. PLoS One. 2014; 9(6): e98665.
70. Harper DM, Demars LR. Primary Strategies for HPV Infection and Cervical Cancer Prevention. Clin Obstet Gynecol. 2014; 57(2): 256-278. doi: 10.1097/GRF.0000000000000027
71. Skinner SR, Szarewski A, Romanowski B, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet. 2014; 384(9961): 2213-2227.
72. Struyf F, Colau B, Wheeler CM, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against incident and persistent infection with non-vaccine oncogenic HPV types using an alternative multiplex type-specific PCR assay for HPV DNA: post hoc analysis from the PATRICIA randomized trial. Clinical and Vaccine Immunology. 2015; 22(2): 235-244.
73. Harper DM, Wall J, Verdenius I. Response to Philanthropic support of HPV vaccination efforts. Prev Med. 2015.
74. Apter D, Wheeler CM, Paavonen J, et al. Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial. Clin Vaccine Immunol. 2015; 22(4): 361-373.
75. Skinner SR, Apter D, Harper DM, et al. Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases: a review of vaccine efficacy. Expert Review of Vaccines. 2015.
76. Kreimer AR, Struyf F, Del Rosario Raymundo MR, et al. Efficacy of Fewer than Three Doses of a HPV-16/18 AS04 adjuvanted Vaccine: a Meta Analysis of Data from the Costa Rica Vaccine Trial and the PATRICIA Trial. Lancet Oncology. 2015.
77. Skinner SR, Wheeler CM, Romanowski B, et al. Progression of HPV infection to cervical lesion or clearance in adult women: analysis of the control arm of the VIVIANE study. International Journal of Cancer. 2015.
78. Hempstead LA, Harper DM. Incorporating Osteopathic Curriculum Into a Dually Accredited Residency Program: Maintaining Osteopathic Identity Under Single Graduate Medical Education Accreditation. Family Medicine. 2015.
79. Skrade JR, Papasian CJ, Harper DM, Kragel PJ. Elastin fibers resembling Sporothrix schenkii in the skin of a patient with acquired immunodeficiency syndrome. Arch of Pathol Lab Med. 1995; 19: 744-748.
80. Skrade JR, Kragel PJ, Papasian CJ, Harper DM. Pseudofungi in a Skin Biopsy from an HIV-Positive Man. Southern Medical Journal Meeting Proceedings. 1994; 87(9): S89.
81. Harper DM. The Dynamically Evolving Field of Cervical Cancer Screening. J Am Board Fam Pract. 1996; 9: 389-390. doi: 10.3122/jabfm.9.5.389
82. Harper DM, Roach MSI. Cervical Intraepithelial Neoplasia in Pregnancy. J Fam Pract. 1996; 42(1): 79-83.
83. Myrick T, Harper DM. Principles of Nonstress Testing in Pregnancy. J Fam Pract. 1996; 43: 443-448.
84. Harper DM. Case Report of Concomitant HSIL with an adenocarcinoma-in-situ. Journal of Lower Genital Track Disease. 1999; 46-47.
85. Philips Z, Whynes D, Jenkins D. HPV Testing: How should decisions be made? In: Harper DM, ed. Papillomavirus Report. 2000; 11(5): 103-106.
86. Harper DM, Philips Z, Jenkins D. HPV Testing: Psychosocial and Cost-Effectiveness Studies of Screening and HPV Disease. Papillomavirus Report. 2001; 12(1): 1-5.
87. Harper DM. Managing Oral Contraceptive Pills in Adolescents: A Practical Approach for the Clinician. Family Pract Recert. 2001; 23: 47-60.
88. Nelson AL, Harper DM, Bauer H, et al. Optimizing treatment of external anogenital warts: Patient applied therapies and other treatments. Ob Gyn News. 2001.
89. Batrya P, Harper DM. Recognizing and Treating Premenstrual Dysphoric Disorder. Journal of Clinical Outcomes Management. 2002; 9: 87-98.
90. Avery DM. Wells MA. Harper DM. Cervico-isthmic corporeal pregnancy with delivery at term: a review of the literature with a case report. Obstetrical & Gynecological Survey. 2009; 64(5): 335-344.
91. Harper DM, Vierthaler SL, Santee JA. Review of Gardasil. Journal of Vaccines and Vaccination. 2010; 1: 107.
92. Harper DM, Vierthaler SL. Next Generation Cancer Protection: The Bivalent HPV Vaccine for Females. ISRN Obstetrics and Gynecology. 2011; 457204: 20.
93. Heitmann E, Harper DM. Prophylactic HPV Vaccines and Prevention of Cervical Intraepithelial Neoplasia. In: Ayhan A, Ed. Vulvar and Cervical Lesions and Prevention. Current Obstetrics and Gynecology Reports. 2012.
94. Mourad WS, Bersano DJ, Greenspan PB, Harper DM. Spontaneous rupture of unscarred uterus in a primigravida with preterm prelabour rupture of membranes. BMJ Case Rep. 2015.
95. Harper DM, DeMars LR. Is LEEP the Cesarean Delivery of Cervical Intraepithelial Neoplasia. Journal of Lower Genital Tract Disease. 1997; 1(4): 257-259.
96. Harper DM, Lonky N, Noller K. Clinical question: ask the experts. J Low Genit Tract Dis. 2004; 8(1): 78-79.
97. Harper DM. Papillomavirus. Self –screening methods for HPV and cytology detection: which one to use? HPV Today. 2004.
98. Harper DM. Why am I scared of HPV? CA- A Journal for Clinicians. 2004.
99. Harper DM. Commentary on Ask the Experts. Journal of Lower Genital Tract Disease. 2004.
100. Harper DM. News Briefs. Can Condoms help clear HPV? CA Cancer J Clin. 2004; 54: 67-71.
101. Harper DM. Are we closer to the prevention of HPV-related diseases? J Fam Pract. 2005; S10-S16.
102. Harper DM, Lonky N, Noller K. Clinical question: ask the experts. J Low Genit Tract Dis. 2004; 8(1): 78-79.
103. Harper DM. HPV vaccine evidence: not just virgins. Commentary for ACP Journal Club. 2007.
104. Harper DM. Understanding before Counseling. Ann Fam Medicine. 2007.
105. Harper DM. Commentary on FUTURE II. International Gynecologic Cancer Society Journal Club. 2007.
106. Harper DM. The HPV Vaccination: Is the Glass Half Empty or Half Full? Trends in Cervical Health. 2007; 3.
107. Harper DM. Predictive Values – What do they mean? What do they tell us about screening tests? Trends in Cervical Health. 2007; 4.
108. Harper DM. Clinical diagnosis of vaginitis was moderately accurate in symptomatic women. Evidence Based Medicine. 2009; 14(3): 88.
109. Franco EL, Harper DM. Vaccination against Human Papillomavirus Infection: A New Paradigm in Cervical Cancer Control. Vaccine. 2005; 23: 1302-1321.
110. Harper DM. Shared Decision Making: Understanding HPV. In: Myers ER, Cox JT, eds. Health and Sexuality. 2005; 10(1): 1-22.
111. Harper DM. Are We Closer to the Prevention of HPV-Related Diseases? HPV Prevention Monograph. Journal of Family Practice Special Edition. 2005; 10-16.
112. Godfrey JA, Harper DM. Toward Optimal Health: Discusses the HPV Vaccine and the Prevention of Cervical Cancer. J of Womens Health. 2007; 16(10): 1397-1401.
113. Harper DM. Human Papillomavirus Vaccines. In: Rose BD, ed. UpToDate. Waltham, MA, 2007.
114. Keam SJ, Harper DM. Human papillomavirus types 16 and 18 vaccine (Recombinant, AS04 Adjuvanted, Adsorbed) [CervarixTM]. Drugs. 2008: 68(3): 359-372.
115. Keam SJ, Harper DM. Human Papillomavirus Types 16 and 18 Vaccine (Recombinant, AS04 Adjuvanted, Adsorbed) [Cervarix trade mark]: Profile Report. Biodrugs. 2008; 22(3): 205-208.
116. Harper DM, Paavonen J. Age for HPV Vaccination. Vaccine. 2008; 26S1: A7-A11.
117. Harper DM. Human Papillomavirus Vaccines. In: UpToDate, Rose, BD (Ed), UpToDate, Waltham, MA. 2008.
118. Harper DM. Impact of vaccination with CervarixTM on subsequent HPV infection and cervical disease in women 15-25 years of age. Gynecologic Oncology. 2008.
119. Harper DM. Prophylactic human papillomavirus vaccines to prevent cervical cancer: review of the Phase II and III trials. Therapy. 2008; 5(3): 313-324.
120. Harper DM. Human Papillomavirus Vaccines. In: UpToDate, Rose, BD (Ed), UpToDate, Waltham, MA, 2009.
121. Harper DM. Preliminary HPV vaccine results for women older than 25 years. Lancet. 2009; 373: 1921-1922.
122. Harper DM. Tema: Vaccine against Human Papillomavirus. Update Medical Records. Lower Genital Tract. 2009; 1(1): 1-4.
123. Harper DM. Prevention of Human Papillomavirus Infections and Associated Diseases by Vaccination: A New Hope for Global Public Health. Public Health Genomics. 2009.
124. Harper DM. Currently Approved Prophylactic HPV Vaccines. Expert Review of Vaccines. 2009; 8(12): 1663-1679. doi: 10.1586/erv.09.123
125. Harper DM. Gardasil needs Consent. Expert Review of Vaccines. 2009; 8(12): 1613-1614. doi: 10.1586/erv.09.120.
126. Harper DM. Current prophylactic HPV vaccines and gynecologic pre-malignancies. Current Opinion in Obstetrics and Gynecology. 2009; 21: 457-464.
127. Harper DM, Williams KB. Prophylactic HPV Vaccines: Current Knowledge of Impact on Gynecologic Premalignancies. Discovery Medicine. 2010.
128. Harper DM, Huh W, Smith McCune, Felix J, Lonky N. HPV vaccine roundtable discussion. Ob Gyn Management. 2010.
129. Harper DM, Nieminen P, Paavonen J, Lehtinen M. Cervical cancer incidence can increase despite HPV vaccination. Lancet Infect Dis. 2010; 10(9): 594-595.
130. Harper DM. Uncertain Long Term Protection against Genital Warts in Males. N Engl J Med. 2011; 364(22): 2164.
131. Steffen J and Harper DM. Congenital Epulis. Consultant for Pediatricians. 2011; 10(5): 167-168.
132. Harper DM, Vierthaler SL. Describe the application of the bivalent against Cervical Cancer. Bivalent HPV Vaccine approved for cervical cancer prevention in females. Experts Iberoamerican Society of Scientific Information Health. 2011.
133. Harper DM, Vierthaler SL. Analyze the characteristics of the quadrivalent HPV vaccine and its use in men and women. Quadrivalent HPV Vaccine approved for males and females for diseases Associated HPV. Experts Iberoamerican Society of Scientific Information Health. 2011.
134. Harper DM, Vierthaler SL. Who should be vaccinated against anal cancer? Lancet Oncology. 2011.
135. Verdenius I, Groner JA, Harper DM. Cross protection against HPV might prevent type replacement. Lancet Infect Dis. 2013; 13(3): 195.
136. Harper DM, Groner JA, Griffith RS, Harper WH. RE: Annual Report to the Nation on the Status of Cancer, 1975-2009, Featuring the Burden and Trends in Human Papillomavirus (HPV)-Associated Cancers and HPV Vaccination Coverage Levels. Journal of the National Cancer Institute. 2013.
137. Talboy GE, Lankachandra K, Harper DM. Prophylactic HPV vaccines for Anal Dysplasia: Speculation overinflates long-term efficacy. Lancet Oncology. 2013.
138. Steffen J, Harper DM. Subperiosteal Abscess. Consultant for Pediatricians. 2012; 11(12): 435-436.
139. Harper DM. Review: Yoga reduces low back pain and back-specific disability. Ann Intern Med. 2013; 159(8): JC13.
140. Harper DM, Wilfling LE, Blanner CF. Review: Combined oral contraceptives are associated with venous thrombosis. Ann Intern Med. 2013; 159(12): JC12.
141. Fernandez LM, Girdler RV, Wright RB, Harper DM. IIV3 reduced flu in HIV- pregnant women and infants, and in HIV+ pregnant women but not their infants. Ann Intern Med. 2015; 162(4): JC6.
142. Fernandez LM, Harper DM. Screening for CIN 3 and Cervical Cancer: Primary HPV esting: The detection of CIN 3 and cervical cancer: HPV primary testing. Medical files data update in Lower Genital Tract. 2015; 12: 1-10.
143. Pendleton E, Ruffin MT, Harper DM. No evidence in US of HPV16/18 cancer precursor reduction. Vaccine. 2015.
144. Harper DM. Colposcopy for Family Physicians. Arch Fam Med. 1994; 3: 400-401. 145. Harper DM. Topical Benzocaine: Does It Alleviate Pain? Who Knows? Am J Obstet Gynecol. 1996; 174(3): 1077.
146. Harper DM. What is a Cost Effectiveness Analysis? Arch Fam Med. 1997; 6(6): 527-528.
147. Harper DM. Treatment Threshold Probability for Vaginitis. Am J Obstet Gynecol. 2000; 183: 517-518.
148. Harper DM. Cost of Publishing Research. J Fam Pract. 2001; 50(12): 1085.
149. Harper DM, Raymond M, Reichert J. Self-screening methods are the next public health improvement for sexually transmitted infection detection. Archives of Pediatrics & Adolescent Medicine. 2002; 156: 1154.
150. Harper DM. Interpretation of Colposcopy Data. J Fam Pract. 2003; 52(5): 390-392. 151. Harper DM, Becker HI, Longacre MR. Assessing patients‚ priorities for the annual exam. 2003.
152. Kaufman HB, Harper DM. Magnification and chromoscopy with the acetic acid test. Endoscopy. 2004; 36(8): 748-750.
153. Kaufman HB, Harper DM. Response to Magnification and Chromoscopy with the Acetic Acid Test. Endoscopy. 2004; 33: 341.